PA Capital’s Viking Therapeutics VKTX Stock Holding History

PA Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-33,987	Closed	-$260K	–	137
2018 Q4	$260K	Buy	+33,987	New	+$406K	0.27%	88

Other funds holding VKTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PA Capital's VKTX Position: Q1 2019 in Review

PA Capital sold out of Viking Therapeutics (VKTX) in Q1 2019, closing a stake of 33,987 shares — an estimated $260K sold.

PA Capital first reported a position in VKTX in Q4 2018 and held it in 1 quarter. The position peaked at $260K in Q4 2018. 164 funds tracked by Wall St. Rank hold VKTX as of Q1 2019.

PA Capital reported no remaining Viking Therapeutics position as of Q1 2019 after selling out during the quarter.
PA Capital sold 33,987 Viking Therapeutics shares in Q1 2019, an estimated $260K.
PA Capital first reported a position in Viking Therapeutics in Q4 2018 and held it in 1 quarter.
PA Capital's Viking Therapeutics position peaked at $260K in Q4 2018.
164 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2019.

Based on PA Capital's 13F filing for Q1 2019, filed 10 May 2019.